Recent Headlines & Media Mentions
Company News
The Connect-One Early Feasibility Study will evaluate the long term use of the Connexus BCI to safely restore speech and enable computer control for people with severe motor impairment
Aug 26, 2026
Paradromics Receives FDA Approval to Expand BCI Access to Personal Computing Devices in Connect-One™ Clinical Study
Expanded device pathway advances development of the Paradromics BCI platform toward greater mobility, independence, and everyday digital access
Neurologist, clinical scientist, and former Verily leader joins Paradromics as company advances first-in-human clinical study
Partnerships with key academic researchers will help translate high-performing BCI technology into commercialized applications
Nov 20, 2025
Paradromics Receives FDA Approval for the Connect-One Clinical Study with the Connexus® Brain-Computer Interface
The study will evaluate the long-term use of Connexus BCI for its ability to safely restore speech and enable computer control for people with severe motor impairment.
Thought Leadership
Looking for additional insights, industry findings, and scientific deep dives?